|
|
Article: Quark Biotech Inc. Receives Equity Investment From Taisho Pharmaceutical Co. Ltd.
- Article from:
- Business Wire
- Article date:
- August 22, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
BIOWIRE2K
CLEVELAND--(BW HealthWire)--Aug. 22, 2001
Quark Biotech Inc. (QBI), announced today that Taisho Pharmaceutical Co. Ltd. of Japan has made an equity investment in the Company.
The investment was made as part of QBI's Series F financing. Financial terms were not disclosed.
QBI and Taisho are currently collaborating on scientific research projects to discover the genes that cause kidney disease and to develop a therapeutic treatment for the cause of the disease, rather than just affecting the symptoms. QBI and Taisho have already completed initial feasibility studies and ...